METiS Therapeutics Analysis: $252M Raised
What is METiS Therapeutics?
METiS Therapeutics develops novel therapeutics using AI, machine learning, and molecular dynamics. Their proprietary predictive AI platform aims to redefine drug discovery and enhance targeted delivery systems for small molecules and gene therapies. The company focuses on creating clinical value by exploring new biological territories.
Location
Cambridge, Massachusetts 02142, United States
Employees
1-10
Founded
2017
Product Features & Capabilities
- AI and ML-driven drug discovery platform
- High-throughput in vivo screening for LNPs
- Proprietary predictive AI platform for drug development
- Targeted delivery systems for RNA and gene therapies
Use Cases
Discover unique lipid nanoparticles with high delivery efficiency; Develop therapeutics targeting multiple organ systems; Collaborate on external programs for AI and ML-developed nanoparticles; Enhance drug delivery systems for serious diseases; Utilize AI for novel therapeutic development
How much METiS Therapeutics raised
Funding - $252M
Other Considerations
Raised $86 million in Series A financing; Appointed Mark Herbert as Chief Business Officer; Partnered with Evopoint Biosciences for licensing; Joined Roche Accelerator for drug development support
See something that needs updating? Suggest edits to this profile.